Terms: = Skin cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Prognosis
134 results:
1. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.
Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
[TBL] [Abstract] [Full Text] [Related]
2. KIF22 promotes the proliferation and glycolysis of melanoma by activating egfr/STAT3 signaling.
Zhong Z; Zhong H
Clinics (Sao Paulo); 2023; 78():100307. PubMed ID: 37944197
[TBL] [Abstract] [Full Text] [Related]
3. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
[TBL] [Abstract] [Full Text] [Related]
4. miRNAs as potential game-changers in melanoma: A comprehensive review.
Abd-Allah GM; Ismail A; El-Mahdy HA; Elsakka EGE; El-Husseiny AA; Abdelmaksoud NM; Salman A; Elkhawaga SY; Doghish AS
Pathol Res Pract; 2023 Apr; 244():154424. PubMed ID: 36989843
[TBL] [Abstract] [Full Text] [Related]
5. Increased FDG Uptake in skin Rashes Caused by egfr Inhibitors.
Erol Fenercioğlu Ö; Cin M; Beyhan E; Şahin R; Çermik TF
Clin Nucl Med; 2023 Jan; 48(1):e46-e47. PubMed ID: 36469080
[TBL] [Abstract] [Full Text] [Related]
6. AIM2 upregulation promotes metastatic progression and PD-L1 expression in lung adenocarcinoma.
Zheng JQ; Lin CH; Lee HH; Chang WM; Li LJ; Su CY; Lee KY; Chiu HW; Lin YF
Cancer Sci; 2023 Jan; 114(1):306-320. PubMed ID: 36104978
[TBL] [Abstract] [Full Text] [Related]
7. Sunvozertinib, a Selective egfr Inhibitor for Previously Treated Non-Small Cell Lung cancer with egfr Exon 20 Insertion Mutations.
Wang M; Yang JC; Mitchell PL; Fang J; Camidge DR; Nian W; Chiu CH; Zhou J; Zhao Y; Su WC; Yang TY; Zhu VW; Millward M; Fan Y; Huang WT; Cheng Y; Jiang L; Brungs D; Bazhenova L; Lee CK; Gao B; Xu Y; Hsu WH; Zheng L; Jänne PA
Cancer Discov; 2022 Jul; 12(7):1676-1689. PubMed ID: 35404393
[TBL] [Abstract] [Full Text] [Related]
8.
Grandits AM; Bromberger S; Heller G; Reinoehl BA; Tomasich E; Schossleitner K; Berghoff AS; Fuereder T; Wieser R
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162973
[TBL] [Abstract] [Full Text] [Related]
9. A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies.
Yao K; Zhou E; Cheng C
Cancer Med; 2022 Feb; 11(4):1232-1243. PubMed ID: 35044091
[TBL] [Abstract] [Full Text] [Related]
10. The immunoexpression of epidermal growth factor receptor in cutaneous squamous cell carcinoma.
Nichita MM; Giurcăneanu C; Mihai MM; Ghigulescu M; Beiu C; Negoiţă SI; Popa LG
Rom J Morphol Embryol; 2021; 62(1):201-208. PubMed ID: 34609422
[TBL] [Abstract] [Full Text] [Related]
11. Aloysia Citrodora Essential Oil Inhibits Melanoma Cell Growth and Migration by Targeting HB-EGF-egfr Signaling.
Salama Y; Jaradat N; Hattori K; Heissig B
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360915
[TBL] [Abstract] [Full Text] [Related]
12. Construction of autophagy prognostic signature and analysis of prospective molecular mechanisms in skin cutaneous melanoma patients.
Liao S; He J; Liu C; Zhang Z; Liao H; Liao Z; Yu C; Guan J; Mo H; Yuan Z; Liang T; Lu Z; Xu G; Wang Z; Chen J; Jiang J; Zhan X
Medicine (Baltimore); 2021 Jun; 100(22):e26219. PubMed ID: 34087900
[TBL] [Abstract] [Full Text] [Related]
13. Successful rechallenge therapy for BRAF/MEK inhibitor-resistant multiple brain metastases of melanoma.
Fukushima H; Iwata Y; Saito K; Sugiura K
J Dermatol; 2021 Aug; 48(8):1291-1295. PubMed ID: 34018641
[TBL] [Abstract] [Full Text] [Related]
14. Loss of DLX3 tumor suppressive function promotes progression of SCC through egfr-erbb2 pathway.
Bajpai D; Mehdizadeh S; Uchiyama A; Inoue Y; Sawaya A; Overmiller A; Brooks SR; Hasneen K; Kellett M; Palazzo E; Motegi SI; Yuspa SH; Cataisson C; Morasso MI
Oncogene; 2021 May; 40(21):3680-3694. PubMed ID: 33947961
[TBL] [Abstract] [Full Text] [Related]
15. NRF2 Enables egfr Signaling in Melanoma Cells.
Kreß JKC; Jessen C; Marquardt A; Hufnagel A; Meierjohann S
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916908
[TBL] [Abstract] [Full Text] [Related]
16. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
[TBL] [Abstract] [Full Text] [Related]
17. Differential Molecular Expression Patterns Associated with Metastasis in Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Mulvaney PM; Massey PR; Yu KK; Drinan JE; Schmults CD
J Invest Dermatol; 2021 Sep; 141(9):2161-2169. PubMed ID: 33771528
[TBL] [Abstract] [Full Text] [Related]
18. Effect of osimertinib in treating patients with first-generation egfr-TKI-resistant advanced non-small cell lung cancer and prognostic analysis.
Yang Y; Guo Y; Wang R; Li J; Zhu H; Guo RTW
J BUON; 2021; 26(1):51-57. PubMed ID: 33721431
[TBL] [Abstract] [Full Text] [Related]
19. Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
Moschos SJ; Eroglu Z; Khushalani NI; Kendra KL; Ansstas G; In GK; Wang P; Liu G; Collichio FA; Googe PB; Carson CC; McKinnon K; Wang HH; Nikolaishvilli-Feinberg N; Ivanova A; Arrowood CC; Garrett-Mead N; Conway KC; Edmiston SN; Ollila DW; Serody JS; Thomas NE; Ivy SP; Agrawal L; Dees EC; Abbruzzese JL
Melanoma Res; 2021 Apr; 31(2):162-172. PubMed ID: 33661190
[TBL] [Abstract] [Full Text] [Related]
20. Determination of hypoxia signature to predict prognosis and the tumor immune microenvironment in melanoma.
Shou Y; Yang L; Yang Y; Zhu X; Li F; Xu J
Mol Omics; 2021 Apr; 17(2):307-316. PubMed ID: 33624645
[TBL] [Abstract] [Full Text] [Related]
[Next]
